[1] Alzheimer’s Disease International. World Alzheimer report 2015. http://www.alz.co.uk/ [2] Chan K Y, Wang W, Wu J J, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis[J]. Lancet. 2013, 381(9882): 2016-2023. [3] Zhang ZX, Zahner GE, Rom?n GC,et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol. 2005 Mar;62(3):447-53. [4] 任树生,金国健. 防治老年慢性病,促进健康老龄化[J]. 中国慢性病预防与控制,2002,03:97-99. [5] 张淑琴.神经病学[M].北京:高等教育出版社,2003.235. [6] Cummings J L, Cummings J L. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res[J]. J Neurol Neurosurg Psychiatry, 1975, 47(5):496-499. [7] Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc. 2009 Mar; 57(3):536-46. doi: 10.1111/j.1532-5415.2008.02122.x. Epub 2009 Jan 29. [8] 劳梅丽,张海英,易西南等. 海南岛阿尔茨海默病的流行病学调查[J]. 中国老年学杂志. 2011(20). [9] Wimo A, Winblad B, J?nsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement. 2010 Mar;6(2):98-103. doi: 10.1016/j.jalz.2010.01.010. [10]王刚,程琦,陈生弟. 阿尔茨海默病疾病经济负担的国内外研究比较和分析[J]. 内科理论与实践. 2009(04). [11] 王晓成. 阿尔茨海默病疾病负担研究[D]. 山西医科大学, 2012. [12] 樊清华. 山西省老年痴呆疾病影响因素分析及卫生服务研究[D]. 山西医科大学, 2012. [13] Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, et al. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain[J]. Neurology. 2006, 67(12): 2186-2191. [14] Zencir M, Kuzu N, et al. Cost of Alzheimer's disease in a developing country setting[J]. International journal of geriatric psychiatry. 2005, 20(7): 616-622. [15]Wang G, Cheng Q, Zhang Set al. Economic impact of dementia in developing countries:all evaluation of Alzheimer-type dementia in Shanghai, China. J Alzheimers Dis,2008,15(1):109-1 15. [16] Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan;50(1):136-45. [17] Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008 Mar 4;148(5):379-97. [18] Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P (2001) A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489–495 [19] Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD (2001) A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481–488 [20]Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B (1999) The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin Ther 21: 1230–1240 [21]Neumann PJ, Hermann RC, Kuntz KM, et al. 1999. Cost effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology 52: 1138–1145. [22]Ikeda S, Yamada Y, Ikegami N. 2002. Economic evaluation of donepezil treatment for Alzheimer’s disease in Japan. Dement Geriatr Cogn Disord 13: 33–39 [23]Fuh JL, Wang SJ. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan. Int J Geriatr Psychiatry. 2008 Jan;23(1):73-8. [24]Julio LB, Warren H, Lidia GP, et al. Cost-Effectiveness of Donepezil in the Treatment of Mild or Moderate Alzheimer’s Disease. Journal of Alzheimer’s Disease 16 (2009) 399–407. [25]Green C, Picot J, Loveman E, et al. 2005. Modeling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease. Pharmacoeconomics 23: 1271–1282. [26]Teipel SJ, Ewers M, Reisig V, et al. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):330-6. Epub 2007 Apr 1. [27]Stewart A , Phillips R , Dempsey G . Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil.[J]. International Journal of Geriatric Psychiatry, 1998, 13(7):445–453. [28]Burns, A. and Fo? rstl, H. (1996a) The Institute of Psychiatry Alzheimer's disease cohort: Part 1? clinical observations. Int. J. Geriatr. Psychiat. 11, 309?320. [29]Martin, D. C., Miller, J. K., Kapoor, W., Arena, V. C. and Boller, F. (1987) A controlled study of survival with dementia. Arch. Neurol. 44, 1122?1126. [30]Wimo A, Winblad B, Engedal K, et al. 2003. Donepezil Nordic Study Group: an economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 15: 44–54. [31]Small GW, Donohue JA, Brooks RL. 1998. An economic evaluation of donepezil in the treatment of Alzheimer’s disease. Clin Ther 20: 838–850.
|